Print
MailMovetis is a European specialty GI company that is focused on improving the lives of millions of patients – both adults and children – by discovering, developing and commercialising innovative treatments targeting gastrointestinal (GI) conditions with a high unmet medical need.
Strategy
Movetis' corporate strategy to become a successful specialty GI company is centred on a number of key elements. These include:
-
Target GI market segments with the highest unmet medical need which together represent approximately 18% of the total GI drug market where little innovation occurred in the past years.
-
Progress the Company’s attractive development pipeline (including M0002 and M0003) in a timely and cost effective manner, thus strengthening the Company’s position in the GI drug market.
-
Benefit from the roll-out of the commercialisation and development strategy of its lead product Resolor, for:
-
Building a direct commercial presence to the GI specialists in selected European markets, i.e. Belgium (including Luxembourg), France, Germany, the Netherlands and the United Kingdom.
-
Building partnerships in other EU markets and to GPs.
-
-
Continue working with Johnson & Johnson to create further value from our products.
-
Successfully complete the label expansion for Resolor.
-
In-license additional novel compounds to help expand the Company’s commercial product offering in the area of GI disease.
-
Embrace the concept of Open Innovation as a way to access world class expertise and resources to assist the Movetis team during the Company’s current phase of rapid corporate development.
In the last four years since Movetis was founded, it has built a business platform that is well positioned to generate significant returns for its shareholders. Movetis management has created a Company which has achieved a number of key milestones and has laid a solid, low-risk platform from which to deliver its goal of developing a successful profitable speciality GI company.
